ILMN — Illumina, Inc. stock price, charts and financials

QT77Illumina, Inc.

Illumina, Inc. (NASDAQ: ILMN) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
190.82
+2.86+1.52%
OverviewShort InterestFilings
ILMNQT77Illumina, Inc.·NASDAQ
190.82+1.52%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MTD+0.52%$1436.82WAT+0.86%$410.35DGX-0.47%$237.23LH-0.19%$318.55GH+0.45%$169.24IQV+1.21%$241.58A+1.40%$148.02NTRA-0.79%$319.56
Snapshot
Index-P/E34.74EPS (ttm)5.41Insider Own3.26%Shs Outstand151.30MPerf Week-8.36%
Market Cap28.44BForward P/E31.29EPS next Y6.01Insider Trans-35.47%Shs Float147.74MPerf Month-2.99%
Enterprise Value29.93BPEG-EPS next Q1.35Inst Own78.33%Short Float5.92%Perf Quarter35.51%
Income827.56MP/S6.33EPS this Y-0.89%Inst Trans-Short Ratio4.72Perf Half Y40.68%
Sales4.49BP/B10.00EPS next Y13.09%ROA12.41%Short Interest8.75MPerf YTD43.31%
Book/sh-P/C25.92EPS next 5Y13.59%ROE31.08%52W High210.15 -9.20%Perf Year99.05%
Cash/sh-P/FCF30.29EPS past 3/5Y- 4.23%ROIC13.54%52W Low89.34 113.59%Perf 3Y2.03%
Dividend Est.-EV/EBITDA21.96Sales past 3/5Y-1.82% 6.02%Gross Margin66.79%Volatility4.15% 3.96%Perf 5Y-60.99%
Dividend TTM-EV/Sales6.66EPS Y/Y TTM169.70%Oper. Margin20.97%ATR (14)8.18Perf 10Y16.22%
Dividend Ex-Date-Quick Ratio1.40Sales Y/Y TTM2.77%Profit Margin18.36%RSI (14)47.98Recom2.58
Dividend Gr. 3/5Y-Current Ratio1.80EPS Q/Q10.08%SMA20-2.98%Beta1.42Target Price196.38
Payout0.00%Debt/Eq0.89Sales Q/Q9.65%SMA504.11%Rel Volume0.90Prev Close187.96
Employees8,600LT Debt/Eq0.73EarningsOct 29SMA20032.15%Avg Volume2.02MPrice190.82
IPO DateJul 28, 2000Option/ShortYes / YesEPS/Sales Surpr.6.82% 2.51%Net Debt/EBITDA1.09Volume1,818,346Change1.52%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-03-26ReiteratedCanaccord GenuityHold$190 → $205
Jul-31-26ReiteratedBernstein$185 → $215
Jul-31-26ReiteratedBarclaysUnderweight$122 → $160
Jul-31-26ReiteratedRBC CapitalOutperform$170 → $230
Jul-31-26ReiteratedGuggenheimBuy$200 → $226
Jul-17-26ReiteratedLeerink PartnersOutperform$250 → $210
Jul-14-26ReiteratedCanaccord GenuityHold$140 → $190
Jun-29-26ReiteratedGuggenheimBuy$180 → $200
Jun-26-26ResumedBernsteinMarket Perform$140 → $185
Jun-10-26UpgradeJP MorganNeutral → Overweight
Latest News
Aug-07-26
Aug-07-2601:01PM
What Makes Illumina (ILMN) a New Strong Buy Stockzacks.com
Aug-06-26
Aug-06-2610:51AM
Here's Why Illumina (ILMN) is a Strong Momentum Stockzacks.com
Aug-05-26
Aug-05-2608:05PM
Standard BioTools Reports Second Quarter 2026 Financial ResultsYahoo
Aug-03-26
Aug-03-2610:16AM
Illumina, Inc. (ILMN) Hits Fresh High: Is There Still Room to Run?zacks.com
Jul-30-26
Jul-30-2608:31PM
Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com
07:53PM
Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcriptseekingalpha.com
07:00PM
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimateszacks.com
04:05PM
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026prnewswire.com
Jul-29-26
Jul-29-2601:33PM
Illumina Earnings: What To Look For From ILMNYahoo
10:16AM
Insights Into Illumina (ILMN) Q2: Wall Street Projections for Key Metricszacks.com
Jul-28-26
Jul-28-2608:00AM
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciencesglobenewswire.com
Jul-24-26
Jul-24-2612:41PM
EXEL vs. ILMN: Which Stock Is the Better Value Option?zacks.com
Jul-22-26
Jul-22-2611:34AM
3 Profitable Stocks We Find RiskyYahoo
06:00AM
Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblownbusinesswire.com
Jul-21-26
Jul-21-2604:21AM
Amova Asset Management Americas Inc. Sells 165,333 Shares of Illumina, Inc. $ILMNdefenseworld.net
Company

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Ownership
Total institutional ownership78.33%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/28/2025
FY 2024
12/29/2024
FY 2023
12/31/2023
FY 2022
1/1/2023
FY 2021
1/2/2022
FY 2020
1/3/2021
FY 2019
12/29/2019
FY 2018
12/31/2018
Total Revenue4,4934,3384,372——————
Cost of Goods Sold Incl. D&A1,4921,4451,511——————
Gross Profit3,0012,8932,861——————
Selling, General and Administrative Excl. Other1,1011,0781,092——————
Research and Development9589511,169——————
Other Operating Expense001,433——————
Operating Income942864-833——————
Interest Expense75101100——————
Unusual Expense
—————————
Non-Operating Income (Expense)148323-246——————
Net Income Before Taxes1,0151,086-1,179——————
Income Taxes19023644——————
Consolidated Net Income825850-1,223——————
Net Income From Continuing Operations825850-1,223——————
Net Income825850-1,223——————
EPS (Recurring)5.415.48-7.69——————
EPS (Basic, Before Extraordinaries)5.415.48-7.69——————
EPS (Diluted)5.365.45-7.69——————
EBITDA1,3631,457-725——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio35.6024.76———————
Price To Sales Ratio6.414.824.92——————
Gross Margin66.7966.6965.44——————
Operating Margin20.9719.92-19.05——————
Net Margin18.3619.59-27.97——————
Shares Outstanding151155159——————
Market Capitalization28,81420,91721,508——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$223.70$183.40$143.09$102.79$62.49● Close Price0.00M37.04M74.08M111.12M148.16MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Meister Keith A.DirectorAug 05 '26Sale199.61283,26956,543,3322,089,425Aug 06
Meister Keith A.DirectorAug 04 '26Sale200.10457,85891,616,5652,372,694Aug 06
Davies Scott MChief Legal OfficerJul 30 '26Sale200.00615123,00020,338Aug 03
Davies Scott MChief Legal OfficerJun 25 '26Sale180.00615110,70020,953Jun 25
Leckman PatriciaSVP, Chief People OfficerJun 05 '26Sale162.59783127,30521,259Jun 09
Leckman PatriciaSVP, Chief People OfficerJun 02 '26Sale162.08784127,06822,042Jun 04
Meister Keith A.DirectorJun 01 '26Sale163.63235,00038,454,1832,830,452Jun 01
Meister Keith A.DirectorMay 29 '26Sale163.51214,59635,088,9153,065,452Jun 01
Ericksen Scott DVP, Chief Accounting OfficerMay 29 '26Sale160.0050080,00014,446Jun 01
Davies Scott MChief Legal OfficerMay 29 '26Sale160.0061598,40021,568Jun 01
Meister Keith A.DirectorMay 28 '26Sale152.27220,00033,499,5323,280,048Jun 01
Meister Keith A.DirectorMay 28 '26Option Exercise102.8224,5622,525,4653,524,610Jun 01
Ericksen Scott DVP, Chief Accounting OfficerMay 28 '26Sale150.101,500225,15014,946Jun 01
Meister Keith A.DirectorMay 14 '26Sale145.34104,39315,172,3813,500,048May 14
Meister Keith A.DirectorMay 13 '26Sale145.55225,06732,759,5933,604,441May 14
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.